Direct interaction of natural and synthetic catechins with signal transducer activator of transcription 1 affects both its phosphorylation and activity

FEBS Journal

Volumn 281, Issue 3, 2014, Pages 724-738

  Menegazzi, Marta ^a   Mariotto, Sofia ^a   Dal Bosco, Martina ^a   Darra, Elena ^a   Vaiana, Nadia ^b   Shoji, Kazuo ^c   Safwat, Abdel Azeim ^d   Marechal, Jean Didier ^e   Perahia, David ^f   Suzuki, Hisanori ^a   Romeo, Sergio ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c SAITAMA UNIVERSITY   (Japan)

^d KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f Ecole Normale Superieure de Cachan   (France)

Author keywords

Gallocatechin 3 gallate; Molecular docking; Site directed mutagenesis; STAT1; Surface plasmon resonance; Synthetic catechins

Indexed keywords

2 (3 HYDROXYPHENYL) 7 HYDROXYCHROMAN 3 YL GALLATE; 2 (3,5 DIHYDROXYPHENYL) 7 HYDROXYCHROMAN 3 YL GALLATE; 3 FLAVANOL 3 BENZOATE; 3 FLAVANOL 3 GALLATE; 3,3',4',5' FLAVANTETROL 3 GALLATE; AFZELECHIN 3 GALLATE; CATECHIN; CATECHIN 3 (ALPHA RESORCYLATE); CATECHIN 3 GALLATE; GALLOCATECHIN 3 (4 SALICYLATE); GALLOCATECHIN 3 (ALPHA RESORCYLATE); GALLOCATECHIN 3 BENZOATE; GALLOCATECHIN 3 GALLATE; GALLOCATECHIN 3 PROTOCATECHUATE; GLUTAMINE; HISTIDINE; JANUS KINASE 2; OXYKOABURAGENIN 3 GALLATE; ROBIDANOL 3 GALLATE; STAT1 PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; SITE DIRECTED MUTAGENESIS; SURFACE PLASMON RESONANCE;

GALLOCATECHIN-3-GALLATE; MOLECULAR DOCKING; SITE-DIRECTED MUTAGENESIS; STAT1; SURFACE PLASMON RESONANCE; SYNTHETIC CATECHINS;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; BINDING SITES; BREAST NEOPLASMS; CATECHIN; CELL LINE, TUMOR; DRUG DESIGN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTANT PROTEINS; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT PROTEINS; STAT1 TRANSCRIPTION FACTOR; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84897048937     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12618     Document Type: Article

References (42)

1. Lee JI & Burckart GJ (1998) Nuclear factor kappa B: important transcription factor and therapeutic target. J Clin Pharmacol 38, 981-993.
2. Zingarelli B, Sheehan M & Wong HM (2003) Nuclear factor-kappaB as a therapeutic target in critical care medicine. Crit Care Med 31, S105-S111.
3. de Prati AC, Ciampa AR, Cavalieri E, Zaffini R, Darra E, Menegazzi M, Suzuki H & Mariotto S (2005) STAT1 as a new molecular target of anti-inflammatory treatment. Curr Med Chem 12, 1819-1828.
4. Darnell JE Jr (1996) The JAK-STAT pathway: summary of initial studies and recent advances. Recent Prog Horm Res 51, 391-403.
5. Nguyen H, Ramana CV, Bayes J & Stark GR (2001) Roles of phosphatidylinositol 3-kinase in interferongamma- dependent phosphorylation of STAT1 on serine 727 and activation of gene expression. J Biol Chem 276, 33361-33368.
6. Blanchette J, Jaramillo M & Olivier M (2003) Signalling events involved in interferon-gamma-inducible macrophage nitric oxide generation. Immunology 108, 513-522.
7. Decker T & Kovarik P (2000) Serine phosphorylation of STATs. Oncogene 19, 2628-2637.
8. Greenhalgh CJ & Hilton DJ (2001) Negative regulation of cytokine signaling. J Leukocyte Biol 70, 348-356.
9. Lin TS, Mahajan S & Frank DA (2000) STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 19, 2496-2504.
10. Kroncke KD, Fehsel K & Kolb-Bachofen V (1998) Inducible nitric oxide synthase in human diseases. Clin Exp Immunol 113, 147-156.
11. Benoist C & Mathis D (1990) Regulation of major histocompatibility complex class-II genes: X, Y and other letters of the alphabet. Annu Rev Immunol 8, 681-715.
12. Glimcher LH & Kara CJ (1992) Sequences and factors: a guide to MHC class-II transcription. Annu Rev Immunol 10, 13-49.
13. Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D et al. (1996) Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84, 431-442.
14. Mangalam AK, Rajagopalan G, Taneja V & David CS (2008) HLA class II transgenic mice mimic human inflammatory diseases. Adv Immunol 97, 65-147.
15. Satoh J & Tabunoki H (2013) Comprehensive profile of ChIP-Seq-based STAT1 target genes suggests the complexity of STAT1-mediated gene regulatory mechanisms. Gene Regul Syst Bio 7, 41-56.
16. Scarabelli TM, Mariotto S, Abdel-Azeim S, Shoji K, Darra E, Stephanou A, Chen-Scarabelli C, Marechal JD, Knight R, Ciampa A et al. (2009) Targeting STAT1 by myricetin and delphinidin provides efficient protection of the heart from ischemia/reperfusioninduced injury. FEBS Lett 583, 531-541.
17. Jeong YI, Kim SW, Jung ID, Lee JS, Chang JH, Lee CM, Chun SH, Yoon MS, Kim GT, Ryu SW et al. (2009) Curcumin suppresses the induction of indoleamine 2, 3-dioxygenase by blocking the Janusactivated kinase-protein kinase Cdelta-STAT1 signaling pathway in interferon-gamma-stimulated murine dendritic cells. J Biol Chem 284, 3700-3708.
18. Choi YB, Kim YI, Lee KS, Kim BS & Kim DG (2004) Protective effect of epigallocatechin gallate on brain damage after transient middle cerebral artery occlusion in rats. Brain Res 1019, 47-54.
19. Crespy V & Williamson G (2004) A review of the health effects of green tea catechins in in vivo animal models. J Nutr 134, 3431S-3440S.
20. Kakuda T (2002) Neuroprotective effects of the green tea components theanine and catechins. Biol Pharm Bull 25, 1513-1518.
21. Sung H, Nah J, Chun S, Park H, Yang SE & Min WK (2000) In vivo antioxidant effect of green tea. Eur J Clin Nutr 54, 527-529.
22. Jankun J, Keck RW, Skrzypczak-Jankun E & Swiercz R (1997) Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res 57, 559-563.
23. Roomi MW, Monterrey JC, Kalinovsky T, Rath M & Niedzwiecki A (2010) Comparative effects of EGCG, green tea and a nutrient mixture on the pattern of MMP-2 and MMP-9 expression in cancer cell lines. Oncol Rep 24, 747-757.
24. Lin YL & Lin IK (1997) (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by downregulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB. Mol Pharmacol 52, 465-472.
25. Menegazzi M, Tedeschi E, Dussin D, De Prati AC, Cavalieri E, Mariotto S & Suzuki H (2001) Antiinterferon gamma action of epigallocatechin-3-gallate mediated by specific inhibition of STAT1 activation. FASEB J 15, 1309-1311.
26. Tedeschi E, Menegazzi M, Yao Y, Suzuki H, Forstermann U & Kleinert H (2004) Green tea inhibits human inducible nitric-oxide synthase expression by down-regulating signal transducer and activator of transcription-1alpha activation. Mol Pharmacol 65, 111-120.
27. Dell'Agli M, Bellosta S, Rizzi L, Galli GV, Canavesi M, Rota F, Parente R, Bosisio E & Romeo S (2005) A structure-activity study for the inhibition of metalloproteinase-9 activity and gene expression by analogues of gallocatechin-3-gallate. Cell Mol Life Sci 62, 2896-2903.
28. Schindler C, Shuai K, Prezioso VR & Darnell JE Jr (1992) Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 257, 809-813.
29. Buzko OV, Bishop AC & Shokat KM (2002) Modified Auto Dock for accurate docking of protein kinase inhibitors. J Comput Aided Mol Des 16, 113-127.
30. Kim H, Lee TH, Hwang YS, Bang MA, Kim KH, Suh JM, Chung HK, Yu DY, Lee KK, Kwon OY et al. (2001) Methimazole as an antioxidant and immunomodulator in thyroid cells: mechanisms involving interferon-gamma signaling and H(2)O(2) scavenging. Mol Pharmacol 60, 972-980.
31. Pawate S, Shen Q, Fan F & Bhat NR (2004) Redox regulation of glial inflammatory response to lipopolysaccharide and interferongamma. J Neurosci Res 77, 540-551.
32. Tsuchiya H (2001) Stereospecificity in membrane effects of catechins. Chem Biol Interact 134, 41-54.
33. Nay B, Arnaudinaud V & Vercauteren J (2001) Gramscale production and applications of optically pure C-13-labelled (+)-catechin and (-)-epicatechin. Eur J Org Chem 2001, 2379-2384.
34. Zaveri NT (2001) Synthesis of a 3, 4, 5-trimethoxybenzoyl ester analogue of epigallocatechin-3-gallate (EGCG): a potential route to the natural product green tea catechin, EGCG. Org Lett 3, 843-846.
35. Tuckmantel W, Kozikowski AP & Romanczyk LJ (1999) Studies in polyphenol chemistry and bioactivity. 1. Preparation of building blocks from (+)-catechin. Procyanidin formation. Synthesis of the cancer cell growth inhibitor, 3-O-galloyl-(2R,3R)-epicatechin-4 beta,8-[3-O-galloyl-(2R,3R)- epicatechin]. J Am Chem Soc 121, 12073-12081.
36. Menegazzi M, Novelli M, Beffy P, D'Aleo V, Tedeschi E, Lupi R, Marchetti P, Suzuki H & Masiello P (2008) Protective effects of St. John's wort extract and its component hyperforin agains cytokine-induced cytotoxicity in a pancreatic b-cell line. Int J Biochem Cell Biol 40, 1509-1521.
37. Laurie AT & Jackson RM (2005) Q-Site Finder: an energy-based method for the prediction of proteinligand binding sites. Bioinformatics 21, 1908-1916.
38. Mao X, Ren Z, Parker GN, Sondermann H, Pastorello MA, Wang W, McMurray JS, Demeler B, Darnell JE Jr & Chen X (2005) Structural bases of unphosphorylated STAT1 association and receptor binding. Mol Cell 17, 761-771.
39. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RH & Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19, 1639-1662.
40. Huey R, Morris GM, Olson AJ & Goodsell DS (2007) A semiempirical free energy force field with chargebased desolvation. J Comput Chem 28, 1145-1152.
41. Duan Z, Bradner J, Greenberg E, Mazitschek R, Foster R, Mahoney J & Seiden MV (2007) 8-benzyl-4-oxo-8- azabicyclo[3.2.1]oct-2-ene-6, 7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. Mol Pharmacol 72, 1137-1145.
42. Ma X & Sayeski PP (2007) Identification of tubulin as a substrate of Jak2 tyrosine kinase and its role in Jak2- dependent signaling. Biochemistry 46, 7153-7162.